Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Therapy Type
3.2. Market Snippet by Drug Delivery Method
3.3. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of castrate-resistant prostate cancer
4.1.1.2. Increasing spending on healthcare
4.1.2. Restraints:
4.1.2.1. Lack of standard therapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Therapy Type
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment.
7.3. Market Attractiveness Index, By Therapy Type Segment
7.3.1. Chemotherapy
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.2. Hormonal Therapy
7.3.3. Immunotherapy
7.3.4. Radiotherapy
8. By Drug Delivery Method
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method Segment.
8.3. Market Attractiveness Index, By Drug Delivery Method Segment
8.3.1. Oral
8.3.1.1. Introduction
8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.2. Injectable
9. By Region
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. The U.S.
9.4.5.2. Canada
9.4.5.3. Mexico
9.5. Europe
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. Germany
9.5.5.2. The U.K.
9.5.5.3. France
9.5.5.4. Italy
9.5.5.5. Spain
9.5.5.6. Rest of Europe
9.6. South America
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.6.5.1. Brazil
9.6.5.2. Argentina
9.6.5.3. Rest of South America
9.7. Asia Pacific
9.7.1. Introduction
9.7.2. Key Region-Specific Dynamics
9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.7.5.1. China
9.7.5.2. India
9.7.5.3. Japan
9.7.5.4. Australia
9.7.5.5. Rest of Asia Pacific
9.8. The Middle East and Africa
9.8.1. Introduction
9.8.2. Key Region-Specific Dynamics
9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Astellas Pharma, Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Bayer AG
11.3. Johnson & Johnson Services Inc.
11.4. Pfizer Inc.
11.5. Sanofi SA
11.6. GlaxoSmithKline PLC
11.7. Northwest Biotherapeutic
11.8. Active Biotech AB
11.9. Spectrum Pharmaceuticals
11.10. Abbott Laboratories
11.11. Other Companies(*LIST NOT EXHAUSTIVE)
12. DataM Intelligence
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us